<GlossaryTerm id="CDR0000817256"><TermName>Ziihera</TermName><TermPronunciation>(zy-HAY-ruh)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat biliary tract cancer that cannot be removed by surgery or has spread to other parts of the body, has been treated with other therapies, and is HER2-positive. It is also being studied in the treatment of other types of cancer. Ziihera binds to a protein called HER2, which is found on some cancer cells. Blocking this protein may help kill cancer cells. It is a type of monoclonal antibody. Also called zanidatamab.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000817809" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Ziihera&quot;" language="en" id="_3"/><MediaLink ref="CDR0000817810" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Ziihera&quot;" language="es" id="_4"/><SpanishTermName>Ziihera</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para el tratamiento del cáncer de vías biliares que no se puede extirpar con cirugía o que se ha diseminado a otras partes del cuerpo, que se ha tratado con otras terapias y es positivo para HER2. También está en estudio para el tratamiento de otros tipos de cáncer. Ziihera se une a una proteína llamada HER2, que se encuentra en algunas células cancerosas. Es posible que bloquear esta proteína ayude a destruir células cancerosas. Es un tipo de anticuerpo monoclonal. También se llama zanidatamab.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2024-12-23</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef UseWith="en" href="CDR0000817225" url="/about-cancer/treatment/drugs/zanidatamab-hrii">Zanidatamab-hrii</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
